Marvel Biosciences has chosen Novotech, an award-winning Australian CRO, to conduct its Phase I clinical trial for MB-204, a drug targeting neurodevelopmental disorders like autism, Rett syndrome, and Fragile X. This partnership leverages Australia's favorable regulatory environment and tax incentives to advance MB-204 efficiently and cost-effectively. MB-204 is a novel adenosine A2A antagonist with potential to treat autism spectrum disorder and depression, marking a key step toward human trials and potential new therapies for underserved neurological conditions.
The FTSE 100 index fell slightly, dragged down by mining stocks reacting to China's slower GDP growth of 4.3% in Q2, its weakest in three years. Despite this, oil prices remained steady amid US-Iran tensions. PayPal shares jumped over 14% following r...
The Goldman Sachs Future Tech Leaders Equity ETF (GTEK) has delivered a 48.9% return year-to-date, nearly doubling the 25% return of the Vanguard Information Technology ETF (VGT). Unlike VGT, which heavily invests in mega-cap tech giants like Nvidia,...
